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Abstract
The aim of this study was to identify new genetic variants associated with the severity of
ankylosing spondylitis (AS). We sequenced the exome of eight patients diagnosed with AS,
selected on the basis of the severity of their clinical parameters. We identified 27 variants in
exons and regulatory regions. The contribution of candidate variants found to AS severity
was validated by genotyping two Spanish cohorts consisting of 180 cases/300 controls and
419 cases/656 controls. Relationships of SNPs and clinical variables with the Bath Ankylos-
ing Spondylitis Disease Activity and Functional Indices BASDAI and BASFI were analyzed.
BASFI was standardized by adjusting for the duration of the disease since the appearance
of the first symptoms. Refining the analysis of SNPs in the two cohorts, we found that the
rs4819554 minor allele G in the promoter of the IL17RA gene was associated with AS
(p<0.005). This variant was also associated with the BASFI score. Classifying AS patients
by the severity of their functional status with respect to BASFI/disease duration of the 60th,
65th, 70th and 75th percentiles, we found the association increased from p60 to p75 (cohort
1: p<0.05 to p<0.01; cohort 2: p<0.01 to p<0.005). Our findings indicate a genetic role for
the IL17/ILRA axis in the development of severe forms of AS.
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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that primarily
involves the axial skeleton, whose susceptibility is clearly attributable to genetic factors [1, 2].
The high frequency of HLA–B27 in patients with spondylarthropathies such as AS (95% of
patients with AS carry B27) has emerged as one of the best examples of a disease association
with an HLA marker[3, 4]. The HLA–B27 family contains a large number of allelic variants or
subtypes that differ in terms of ethnic distribution and whose heterogeneity has been previ-
ously determined in various populations[5]. However, population studies have indicated that
only 2–5% of HLA–B27positive subjects develop the disease[6, 7]. These data suggest that this
biomarker is clearly not sufficient on its own to cause disease, and it is evident that susceptibil-
ity to AS is affected by other environmental and genetic factors[8].
Recently, genome-wide association studies have shown that non-major histocompatibility
complex (non-MHC) regions are involved in disease susceptibility[9–11], specifically genomic
regions such as 1p, 2p, 2q, 3p, 9q, 10q, 11p, 16q, and 19q[12]. In fact, some studies have associ-
ated different variants of ERAP1 and IL23R and KIR genes with AS[13–16]. Despite the great
advances stemming from the GWAS studies, some unexpected challenges also emerged[17,
18]. Genetic factors also influence disease prognosis and clinical outcome, but little is known
about this association.
The functional severity, radiographic severity and activity of the AS, respectively measured
with the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondy-
litis Radiology Index (BASRI) and the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI), can help us study the pathogenesis of the disease. Recently, several studies have
associated some biomarkers with the functional and radiographic severity status of the patient
[19, 20] and with their BASDAI score[21].
Thus, the aim of this study was to determine whether common and rare DNA variants in
the exome regions and in the promoters are associated with the risk of developing AS or have
an effect on disease severity. Exome sequencing was used for these purposes in a group of
patients with advanced disease status. It is a powerful tool that can help us identify rare genetic
traits that affect disease evolution. We extend the exome sequencing to promoter regions, iden-
tifying minor variants as possible biomarkers associated with disease severity.
Patients and Methods
Study population
Eight AS patients were selected for exome sequencing on the basis of severe clinical parameters
(mean BASFI, 6.8 ± 1.1; mean BASDAI, 6.4 ± 1.8). These patients had severe pain along the
spine and/or in the pelvis, sacroiliac joints, heels and chest. The high degree of joint damage
made it difficult for them to do their daily activities. For validation purposes, two Spanish
cohorts of patients (S1 Table) and healthy controls were also selected. Cohort 1 comprised 180
patients with AS and 300 healthy control subjects, recruited from theHospital Universitario
Central de Asturias (Oviedo, Spain) and the Hospital Universitario A Coruña (A Coruña,
Spain).For the replication phase (Cohort 2), 419 patients with AS and 656 healthy controls
were recruited from theHospital Universitario Puerta de Hierro (Madrid, Spain), which is a
participant institution in the Spanish National Spondyloarthropathies Registry (REGISPON-
SER) (Table 1). There were 599 unrelated patients with AS (mean age, 50.3 ±10.5 years; 78.3%
men) and 956 healthy controls (mean age, 52.0 ±16.0 years; 59% men). All patients were diag-
nosed in Rheumatology Units in accordance with the Modified New York Criteria and had at
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least 10 years of follow-up from the first symptoms of the disease. The disease was defined as
severe or non-severe according to the BASDAI and the BASFI.
The study was granted ethical approval by the Regional Ethics Committee for Clinical
Investigation of the participating hospitals (Regional Ethics Committee of Clinical Research of
Principado de Asturias; Ethics Committee of Clinical Research of Galicia; Regional Ethics
Committee of Clinical Research of Madrid) and conducted in accordance with the Declaration
of Helsinki. All patients and control subjects gave their written informed consent before enroll-
ing in the study.
Whole-exome sequencing and analysis
Whole-exome sequencing was performed in eight AS patients with severe forms of the disease
using SureSelect Target Enrichment Human All Exon + UTR kit (71mb) (Agilent Technolo-
gies) compatible with the SOLID platform. We evaluated the quality and quantity of DNA
patients by agarose gel electrophoresis, measuring absorbance at 260 nm withNanoDrop1000
and quantifying the results by fluorescence Qubit.
The quality and quantity of the libraries obtained were evaluated by Qubit and an Agilent
2100 Bioanalyzer. The libraries were subjected to a process of emulsion PCR for clonal amplifi-
cation fragments, followed by enrichment and chemical modification to allow loading in the
reaction chamber, employing the protocols and recommendations provided by Life Technolo-
gies for sequencing with the SOLiD 5500XL system.
The quality and quantity of the microspheres obtained from the libraries were estimated
taking into account the parameters derived from the work-flow analysis (WFA). The reactions
for obtaining sequences of 75nt+25 nt (paired-end) were subsequently carried out in a SOLiD
Table 1. A) IL17RA rs4819554 distribution in cohort 1. Statistical significance (p<0.05) was lost when a Bonferroni correction was applied. B) IL17RA
rs4819554 distribution in cohort 2.
A) Cohort 1
Allele Patients (2n = 360) Controls (2n = 600) pc OR (95% CI)
A 273 (75.8) 486 (81) NS -
G 87 (24.2) 114 (19)
Genotype Patients (n = 180) Controls (n = 300) p (AA vs. Gx) OR (95% CI)
AA 104 (57.8) 194 (64.7) NS -
AG 65 (36.1) 98 (32.7)
GG 11 (6.1) 8 (2.7)
B) Cohort 2
Allele Patients (2n = 838) Controls (2n = 1312) p OR (95% CI)
A 639 (76.3) 1052 (80.2) <0.05 1.26 (1.02–1.55)
G 199 (23.7) 260 (19.8)
Genotype Patients (n = 419) Controls (n = 656) p (AA vs. Gx) OR (95% CI)
AA 240 (57.3) 416 (63.4) <0.05 1.29 (1.01–1.66)
AG 159 (37.9) 220 (33.5)
GG 20 (4.8) 20 (3)
Cohort 1: From the Hospital Universitario Central de Asturias (Oviedo, Spain) and the Hospital Universitario A Coruña (A Coruña, Spain).
Cohort 2: From the Hospital Universitario Puerta de Hierro (Madrid, Spain) which participated in the Spanish National Spondyloarthropathies Registry
(REGISPONSER).
Notes: pc, Bonferroni-adjusted probability.
Hardy-Weinberg equilibrium: p>0.05
doi:10.1371/journal.pone.0158905.t001
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5500XL system. Data quality was assessed from the parameters estimated by the sequencing
software.
Bioscope version 1.3 was used to map and pair the reads to the NCBI human genome refer-
ence (hg19, GRCh37). Single nucleotide variants (SNVs) and indels were selected for subse-
quent analysis by the following four criteria. First, all SNPs selected were new variants that had
not previously been associated with AS. Also all the selected variants resulted in a non-synony-
mous aminoacid change in the protein that was able to modify the functionality based on a pre-
dictive model. The SNPs on the promoter should be present in regions for transcription factor
binding also based on a predictive model. Second, the MAF differences of each SNP should be
greater than 20% between selected patients and the general population. Third, the depth of cov-
erage of the exome sequencing should be greater than 30. Finally, these SNPs should be
included in genes of immunological relevance or that encode proteins associated with osteo-
genesis and/or cellular adhesion. We also searched for previously unreported protein-altering
variants that occurred in more than one subject and in the promoter.
SNVs and indels were called using Samtools-0.1.18[22], Picard tools-1.67 and the Genome
Analysis Toolkit (GATK)[23].
SNV validation
57 significant SNVs obtained from the exome sequencing analysis were reanalyzed by Sanger
sequencing.
Single nucleotide polymorphism genotyping
The SNVs confirmed by Sanger sequencing were analyzed in the two cohorts of patients and
controls. These variants were genotyped by amplifying the region containing the polymorphic
site and hybridization with fluorescent-labeled probes in an RT-PCR based on TaqMan1 SNP
Genotyping Assays (Applied Biosystems). Genomic DNA from patients and healthy donors
was extracted from peripheral blood with the Magtration-MagaZorb DNA Common Kit-200
N using the Magtration 12GC system (Precision System Science Co., Ltd., Woerrstadt, Ger-
many) and the Maxwell1 16 Blood Purification Kit using the Maxwell1 16 Instrument (Pro-
mega Corporation, Madison, Wisconsin, USA).
Statistical analysis
The χ2 test was used to examine differences in genotype and allele frequencies between the
groups and to determine deviations from the Hardy-Weinberg equilibrium. Odds ratios (ORs)
and their 95% confidence intervals (CIs) were also calculated. Student’s t test for independent
samples was used to compare differences in means between the groups. Standard linear regres-
sion was used to relate disease severity measures (BASFI and BASDAI) with the genotype. The
association between AS functional severity and the presence or absence of the IL17RA SNP
was assessed using the BASFI index. To standardize the measure of functional severity, we cor-
rected the BASFI for the duration of AS, from the onset of the disease, taken as the appearance
of the first symptoms, until the time of the last BASFI and BASDAI score measure. The average
time of evolution from disease onset was 10 years. We performed three association analyses
using the χ2 test, each with different criteria for defining the functionally severe group. Based
on the clinical features, we classified the patients in the top 60th (p60), 65th (p65), 70th (p70) or
75th (p75) percentile of BASFI/disease duration in the severe group[13]. The magnitude of
association was expressed as an OR and its 95% CI.
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Results
Exome sequencing analysis
Based on the aforementioned criteria, we established which SNPs were of potential interest in
this study. We selected 57 SNPs that we then validated by Sanger sequencing in order to
exclude false positives. This left 27 SNPs, all of which were present in genes associated with
inflammation processes, bone and cartilage synthesis, and misfolded protein or other processes
(S2 Table). The SNPs analyzed were all exon missense variants or promoter variants. A test val-
idation of the deviation from Hardy-Weinberg equilibrium was performed for each SNP.
IL17RA rs4819554 polymorphism analysis
Refining these SNPs, we found that the rs4819554 located in the IL17RA promoter region was
significantly associated with AS in cohort 1 (minor allele G, p<0.05; OR = 1.36), but not when
a Bonferroni correction was applied (Table 1). Nevertheless, when we analyzed this SNP in
cohort 2 it was clearly associated with AS (minor allele G, p<0.05; OR = 1.26) (Table 1). When
the two cohorts were combined this allele was also more frequent in patients than in the con-
trol group, (p<0.005; OR = 1.29) (data not shown).
Subsequently, we analyzed the association of rs4819554 SNP with the BASFI and BASDAI
and found that the presence of this SNP was associated with the severity of AS (Table 2). The
BASFI score was higher in patients with the Gx genotype (p<0.01) and the association per-
sisted after correcting for the duration of disease evolution (p<0.01). These patterns were also
found in cohort 2. However, the BASDAI score only had a statistically significant association
in the second cohort (p<0.05), including when we adjusted the score for the duration of disease
evolution (p<0.05). We then corrected the BASFI association for the duration of AS since the
onset of the disease [BASFI/t]. A representative of the SNP rs4819554 association with [BASFI/
t] is shown in Fig 1. The most highly significant association was with p75 (Cohort 1, p<0.01;
Cohort 2, p<0.005).
In conclusion, the rs4819554 SNP was found to be associated with patients with poor evolu-
tion, as determined by the BASFI score.
Discussion
Several genome-wide association studies (GWASs) have described many SNPs in the genome
that are associated with AS susceptibility[11, 24]. Although some studies have related various
gene variants to radiographic and functional severity in AS[19, 20], to our knowledge the
Table 2. Clinical characteristics related to disease severity with respect to the rs4819554 genotype distribution.
Cohort 1 (n = 180) Cohort 2 (n = 419) Both cohorts (n = 599)
AA genotype
n = 104
Gx genotype
n = 76
p AA genotype
n = 240
Gx genotype
n = 179
p AA genotype
n = 344
Gx genotype
n = 255
p
BASDAI, mean (SD) 3 (2.2) 3.3 (2.2) NS 3.9 (2.5) 4.4 (2.3) <0.05 3.7 (2.7) 4.1 (2.6) <0.05
BASDAI adjusted by duration
of disease evolution, mean
(SD)
0.19 (0.29) 0.23 (0.35) NS 0.18 (0.12) 0.22 (0.13) <0.05 0.19 (0.24) 0.22 (0.29) NS
BASFI, mean (SD) 3.1 (2.6) 4.2 (2.7) <0.01 3.7 (2.7) 4.3 (2.8) <0.05 3.7 (2.7) 4.2 (2.8) <0.05
BASFI adjusted by duration of
disease evolution, mean (SD)
0.15 (0.13) 0.21 (0.14) <0.01 0.15 (0.12) 0.19 (0.13) <0.01 0.15 (1.4) 0.19 (1.4) <0.01
Note: Gx genotype includes GG and GA genotypes
doi:10.1371/journal.pone.0158905.t002
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present study is the first to use exome sequencing to examine the association of allelic variants
with the functional severity of the patient, as measured by the BASFI.
We performed whole-exome sequencing plus promoter regions in a subset of severe AS
patients to identify novel and minor variants contributing to AS risk. After sequencing, we
found that the rs4819554 G minor allele, located in the promoter of IL17RA gene, was associ-
ated with AS in the two clinical cohorts. This variant has recently been related to alopecia
areata susceptibility[25] and psoriasis[26], and we had found it to be responsible for impaired
renal function[27]. Conversely, this SNP was not previously associated to AS in GWAS proba-
bly due to a different point of view in patient selection. We have incised in clinical characteris-
tics, as previously described in Patients and Methods section. Moreover, we observed that the
rs4819554 polymorphism can influence the severity of the functional status of AS patients,
measured as BASFI/t duration and BASDAI/t duration scores. These findings suggest that the
rs4819554 may be a good biomarker of the severity of the disease, and that it could be applied
early in the course of AS in patients identified as having a potentially severe functional
outcome.
The IL-17 family comprises a group of cytokines made up of six members (IL-17A to F) and
five receptors (IL-17RA to E) with an active role in the acute and chronic immune responses
[28, 29]. The prototypical member of the IL17 family, IL-17A, defines a new subset of CD4+
effector T (Th17) cells and this cytokine induces the production of inflammatory mediators
from epithelial and endothelial cells and fibroblasts[30]. In relation to AS, the levels of IL17A
are higher in the sera and synovial fluid of patients[31, 32], and a high frequency of Th17 cells
Fig 1. IL17RA rs4819554 genotype frequency (Gx) based on BASFI/t-duration. Note:Cohort 1. (BASFI/t p75 vs. controls: 48.0% vs. 35.3%, p<0.01).
R2 = 65%.Cohort 2. (BASFI/t p75 vs. controls: 53.2% vs. 36.6%, p<0.005) R2 = 95%.
doi:10.1371/journal.pone.0158905.g001
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has been found in the peripheral blood, synovial fluid and inflamed bone marrow of patients
with AS, implying a role for these cells in inflammation in AS[33, 34].
The IL17RA receptor might be crucial to the majority of IL17 family members[35]. This
receptor is expressed in many types of cells, including epithelial cells, fibroblasts, B and T lym-
phocytes, myelomonocytic cells and marrow stromal cells[29]. Several common polymor-
phisms in the genes of the IL-17 family have been linked to the risk of developing cancer, and
autoimmune and inflammatory diseases[36–38]. However, none of these studies evaluated the
rs4819554 SNP in IL-17RA.
The rs4819554 SNP is located in the promoter region of IL17RA and could thus have a
functional effect by inducing or inhibiting the transcription of the gene. Sequencing analysis
revealed other promoter polymorphisms in linkage disequilibrium with rs4819554 that were
predicted to affect the binding of transcription factors (TFs), such as those of the Ikaros (IK)
family. This family of TFs is involved in regulating Th17 cell differentiation through the pro-
motion of Th17 lineage-determining genes and in repressing the expression of genes that limit
the development of Th17[39]. A putative effect of these promoter polymorphisms on TF bind-
ing could also explain the reported differences in IL17RA protein expression and the amount
of mRNA in CD14+ peripheral blood monocytes between individuals with different genotypes
[39].
Interleukin (IL)-23 is considered to be a central cytokine that acts in AS to regulate IL17
production. It is known from a murine model of AS that IL-23+ CD3+/CD4-/CD8- resident T
cells are able to release IL-17, which is important for driving spinal inflammation. Levels of
IL17A have been found to be higher in the sera and synovial fluid of AS patients[32]. Th17
cells are particularly abundant in the peripheral blood, synovial fluid and inflamed bone mar-
row of patients with AS, suggesting that they have a role in inflammation in AS. Several other
cell types (especially Type 3 innate immune cells) defined as Lyn−IL-23R+NKp44+Tbet+RORc−
are also important sources for IL-17 production in AS. Other polymorphisms of the IL-23/IL-
17A axis, such as SNPs in TRAF3IP2 that code for the adaptor Act1, a downstream target of
IL-17R, which confers susceptibility to psoriatic arthritis, may be evaluated in AS[40]. Further
studies to determine the effect of rs4819554 on gene expression would be of particular interest.
In conclusion, we report an association between the rs4819554 SNP in the promoter region
of IL17RA and the risk of AS, with a stronger association in individuals with severe AS with
respect to the BASFI score and the duration of the disease. Our results need to be validated in
other populations, and other studies are required to measure the levels of circulating IL17RA
in blood and synovial fluid and to confirm our results concerning the effect of this polymor-
phism on gene expression. The study of new biomarkers in relation to AS progression could
help us develop a predictive algorithm based on the treatment regimen.
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